Dexcom stock holds near a 52-week high after a Q2 beat
Published on 08/25/2026 at 19:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DexCom Inc. (US2521311074) is trading at $90.36, up 0.77% from the previous close, after a July 30, 2026 quarter that delivered $1.31 billion in revenue and $0.70 in earnings per share.
The same report marked a clear beat versus consensus, with revenue ahead of $1.29 billion and EPS ahead of $0.61. That left the shares just below the 52-week high of $92.59 and above the 52-week low of $54.11.
Q2 still drives the story
MarketBeat's August 25, 2026 coverage said Dexcom's quarterly revenue rose 13.1% year over year, while the company posted a net margin of 20.12% and return on equity of 35.94%. The same piece said analysts expect $2.64 in EPS for the current fiscal year, which keeps the valuation debate tied to execution rather than the top line alone.
That setup matters because the market is already pricing a lot of that growth into the name. A market data snapshot on August 25, 2026 put the company's market cap at $34.36 billion and its price-to-earnings ratio at 35.99.
Price action stays firm
Dexcom opened at $91.06 and traded between $90.10 and $91.14 in the latest U.S. session shown in Yahoo Finance's live quote, with volume at 679,861 shares and an intraday market cap of $34.098 billion. The stock is up 36.15% year to date, while the S&P 500 is up 11.93% over the same period.
That gap helps explain why the shares keep attracting both growth buyers and valuation skeptics. One analyst update in the same quote page lists a 1-year target estimate of $94.12 and a latest rating dated August 4, 2026 that lifted a target to $96.
What Dexcom sells
Dexcom's main products include G7, G7 15 Day, G6, Dexcom ONE+, Stelo, Dexcom Share and Dexcom Follow, all centered on continuous glucose monitoring for diabetes care. That product mix gives the company exposure to both established insulin users and newer over-the-counter use cases.
Shares and valuation
At $90.36, the stock sits close to the top of its 52-week range and well above its 200-day moving average of $71.07. Investors are still weighing whether the July 30, 2026 earnings beat and the 13.1% revenue growth justify a forward P/E near 36.
More on Dexcom stock
Investor relations
Company facts
Company: DexCom Inc.
ISIN: US2521311074
Ticker: DXCM
Exchange: Nasdaq
Price (as of August 25, 2026, 11:01 a.m. ET): $90.36 USD
Market cap: $34.36 billion
Sector / Industry: Healthcare / Medical Devices
Index membership: Nasdaq-100
Next earnings date: October 29, 2026
